Customize
Quick Links

Accreditation/
Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
Physicians’ Education Resource ®, LLC.
All rights reserved.

AACR: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in Trials

AACR: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in Trials


Date: Monday, April 16, 2018

Dinner and Scientific Session: 6:30 PM – 9:00 PM

Location:
Chicago Hyatt Regency
151 East Wacker Drive
Chicago, IL 60601
Room: Crystal Ballroom, BC

Overview

Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in Trials is a live symposium to be held adjunct to the annual meeting in Chicago. Frontline decision making and treatment sequencing in the management of patients with non–small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR) gene continue to change as new evidence emerges. For example, third-generation EGFR tyrosine kinase inhibitors have demonstrated improved outcomes compared with previous first-line standards of care, and plasma-based molecular testing has made possible a less invasive and more rapid approach to tumor profiling compared with standard tissue-based testing.

These exciting developments nevertheless have led to a reassessment of subsequent lines of therapy; which tumor-testing strategies can facilitate diagnosis along the disease continuum; management of patients with central nervous system (CNS) involvement; and practical approaches to mitigate the impact of treatment-related toxicities.

To meet this educational need, this cutting-edge program will feature a panel of world-class experts in lung cancer who will review recent practice-changing data and state-of-the-art approaches for patients with EGFR mutation‒positive NSCLC, with an emphasis on examining the evidence and trials, and how to interpret and apply the data in practice. Key topics to be addressed by faculty include:

  • New standards of care for first-line therapy of patients with EGFR mutation‒positive NSCLC
  • Navigating the changing landscape for subsequent lines of therapy
  • Incorporating liquid-based and tissue-based molecular testing to optimize therapeutic decision making
  • Assessing multiple therapeutic modalities for managing patients with CNS metastases

The symposium will be held on April 16, 2018, from 7:00 pm -9:00 pm. Please join us in Chicago for expert advice on evolving treatment paradigms for patients with EGFR mutation‒positive NSCLC. You won’t want to miss this activity!

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Target Audience:

This educational program is directed toward the AACR audience, including medical oncologists and cancer researchers. Other healthcare professionals involved in the study or treatment of cancer are also invited to participate.

Learning Objectives

Upon completion of this activity, participants should be better prepared to:

  • Delineate key tumor-testing approaches utilized in clinical trials that have evaluated frontline and next-line strategies in the setting of advanced EGFR-mutated NSCLC
  • Explain key landmark trial findings that inform therapeutic selection in the initial management of patients with advanced EGFR-mutated NSCLC
  • Describe the impact on clinical decision making that resistance, CNS metastases, and the extent of metastases have in managing patients with advanced EGFR-mutated NSCLC
  • Develop a personalized treatment plan for patients with advanced NSCLC to optimize outcomes and proactively manage treatment-related toxicities in multiple lines of care


Program Chair

Pasi A. Jänne, MD, PhDMD
Director, Lowe Center for Thoracic Oncology
Professor of Medicine, Harvard Medical School
Director, Belfer Center for Applied Cancer Science
Dana Farber Cancer Institute
Boston, MA

 







Become a Member

Forgot Password?
Filter By